Table 5

Demographic and clinical characteristics in age-matched patients with AQP4+NMOSD and MS without clinical relapses and disability progression at MRI-1

AQP4+NMOSD (n=20)RRMS (n=20)p value
Demographic
 Female (%)18/20 (90.0%)15/20 (75.0%)0.41
 Age (years)50.0 (16.5) (34–67)48.0 (14.0) (35–67)0.45
Clinical
 Disease duration (years)2.9 (10.3) (0.25–36.7)13.9 (13.5) (1.6–27.1)0.004*
 EDSS score4.5 (4.1) (1.0–7.0)3.5 (4.8) (0.0–7.0)0.67
 ARR from disease onset0.73 (0.70) (0.32–4.0)0.51 (0.38) (0.14–2.1)0.045*
 Months from last attack17.7 (26.6) (2.4–61.9)37.4 (56.7) (3.1–147.2)0.19
 Months from DMD initiation9.7 (16.4) (1.2–68.1)29.2 (61.2) (1.4–172.4)0.009*
 Oligoclonal bands positivity3/14 (15%)9/15 (60%)0.06
Number of patients with a history of
 Optic neuritis13/20 (65%)
 Myelitis16/20 (80%)
 Long cord lesion11/20 (55%)
 Brain stem lesion5/20 (25%)
 Area postrema syndrome1/20 (5%)
 Cerebral syndrome4/20 (20%)
DMD
 Interferon β−1a05
 Interferon β−1b04
 Fingolimod08
 Dimethyl fumarate03
 Natalizumab00
 Prednisolone150
 Prednisolone+azathioprine20
 Prednisolone+eculizumab10
 None20
  • Data are presented as median number (%) or (IQR) (range). *p<0.05.

  • Months from DMD initiation indicate period between the start of the same DMD given before MRI-1 and the date MRI-1 was performed.

  • AQP4+NMOSD, anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; ARR, annualised relapse rate; DMD, disease-modifying drug; EDSS, Kurtzke’s Expanded Disability Status Scale; PRMS, relapsing-remitting multiple sclerosis.